Key Points
- To evaluate the distinct pharmacological and biochemical profiles among low-molecular-weight heparins and assess their implications for the management of thrombosis.
- Reviewed comparative anticoagulant assays evaluating anti-IIa and anti-Xa specific activity profiles across different low-molecular-weight heparin (LMWH) formulations.
- Assessed dose- and time-dependent antithrombotic, fibrinolytic, and endothelial mediator responses in experimental animal models and clinical trials.
- Anti-IIa specific activity in anticoagulant assays ranges from 35 to 45 U/mg, whereas anti-Xa activity ranges from 80 to 145 U/mg across different LMWH products.
- LMWHs demonstrate sustained antithrombotic efficacy without detectable ex vivo anticoagulant actions, mediated in part by the release of tissue factor pathway inhibitor and von Willebrand factor.
- Repeated administration generates product-dependent escalation of antithrombotic and hemorrhagic effects, distinguishing individual formulations from new alternative anticoagulants and generics.
Structured PICO
IInterventionLow-molecular-weight heparins (LMWHs)
LMWHs have distinct pharmacological profiles based on manufacturing differences, which impact their antithrombotic effects and clinical utility compared to emerging alternatives.